Диссертация (1141102), страница 17
Текст из файла (страница 17)
Aksentijevich, S.L. Masters, P.J. Ferguson,et al // N Engl J Med. – 2009. - №360(23). – Р.2426-2437.110.American Diabetes Association: Standarts of medical care in Diabetes(Position Statement) // Diabetes Care. – 2006. - № 29. - P. 4-42.111.American Diabetes Association: Standarts of medical care in Diabetes //Diabetes Care.
– 2009. - № 32(1). - P. 13-61.112.Aragon-Sanchez, J. Treatment of diabetic foot osteomyelitis: a surgicalcritique / J. Aragon-Sanchez // Int. J. Low Extrem. Wounds. – 2010. – vol. 9. –37-59.100113.Armstrong, D.G. Guest Editorial: are diabetes related wounds andamputations worse than cancer? / D.G. Armstrong // Int. Wound J. – 2007. – vol.4. – p. 286-287.114.Armstrong, D.G. Who is at risk for diabetic foot ulceration? / D.G.Armstrong, L.A. Lavery // Clin. Podiatr. Med. Surg.
– 2008. – vol. 15 – p. 11-19.115.Arslan, F. Myocardial ischemia/reperfusion injury is mediated byleukocytic toll-like receptor-2 and reduced by systemic administration of a novelanti-toll-like receptor-2 antibody / F. Arslan, M.B. Smeets, L.A. O'Neill, et al. //Circulation. – 2010. - №121(1). – Р.80-90.116.Bamberger, D.M. Diagnosis and treatment of osteomyelitis / D.MBamberger // Compr. Ther.
- 2000. - V. 26, №2. - P. 89-95.117.Ben-Sasson, S.Z. IL-1 acts directly on CD4 T cells to enhance theirantigen-driven expansion and differentiation / S.Z. Ben-Sasson, J. Hu-Li, J.Quiel, et al. // Proc Natl Acad Sci USA. – 2009. - №106(17). – Р.7119-7124.118.Berendt, A.R. Specific guidelines for treatment of diabetic footosteomyelitis.
/ A.R. Berendt // Diabetes Metab Res Rev. – 2008. – vol. 24. – p.190-191.119.Bergsbaken, T. Pyroptosis: host cell death and inflammation / T.Bergsbaken, S.L. Fink, B.T. Cookson // Nat Rev Microbiol. – 2009. -№7(2). –Р.99-109.120.Blumberg, H. Opposing activities of two novel members of the IL-1 ligandfamily regulate skin inflammation / H. Blumberg, H. Dinh, E.S. Trueblood, et al.// J Exp Med. – 2007. - №204(11). – Р.2603-2614.121.Bonham, P.A. A critical review of the literature: part 1: diagnosingosteomyelitis in patients with diabetes and foot ulcers. / P.A.
Bonham // J. WoundOstomy Continence Nurse. – 2001. – Vol. 28. – P.73-88.122.Bonham, P.A. A critical review of the literature: part 2: antibiotic treatmentof osteomyelitis in patients with diabetes and foot ulcers. / P.A. Bonham // J.Wound Ostomy Continence Nurse. – 2001. – Vol. 28. – P.141-149.101123.Bulek, K. The essential role of single Ig IL-1 receptor-relatedmolecule/Toll IL-1R8 in regulation of Th2 immune response / K. Bulek, S.Swaidani, J. Qin, et al.
// J Immunol. – 2009.- №182(5). – Р.2601-2609.124.Carmi, Y. The role of macrophage-derived IL-1 in induction andmaintenance of angiogenesis / Y. Carmi, E. Voronov, S. Dotan, et al. // JImmunol. – 2009. - №183. – Р.4705-4714.125.Carriere, V. IL-33, the IL-1-like cytokine ligand for ST2 receptor, is achromatin-associated nuclear factor in vivo / V. Carriere, L. Roussel, N. Ortega etal. // Proc Natl Acad Sci U S A. – 2007.
- №104(1). – Р.282-287.126.Chen, C.J. Identification of a key pathway required for the sterileinflammatory response triggered by dying cells / C.J. Chen, H. Kono, D.Golenbock // Nat Med. – 2007. - №13(7). – Р.851-856.127.Chevalier, X. Intraarticular injection of anakinra in osteoarthritis of theknee: a multicenter, randomized, double-blind, placebo-controlled study /Chevalier X, Goupille P, Beaulieu AD, et al. // Arthritis Rheum.
– 2009. №61(3). – Р.344-352.128.Chizzolini, C. Prostaglandin E2 synergistically with interleukin-23 favorshuman Th17 expansion / Chizzolini C, Chicheportiche R, Alvarez M, et al. //Blood. – 2008. - №112(9). – Р.3696-3703.129.Chung, Y. Critical regulation of early Th17 cell differentiation byinterleukin-1 signaling / Chung Y, Chang SH, Martinez GJ, et al. // Immunity. –2009. - №30(4). – Р.
576-587.130.Cierny, G. A Clinical Staging System for Adult Osteomyelitis / G. Cierny,J.T. Mader, J.J. Penninck // Clinical Orthopaedics and Related Research. - 2003. №414 – P. 7-24131.Cierny, G. Treatment of chronic infection / G. Cierny, D. Doreen // Journalof the American academy of orthopaedic surgeons – 2006. - V. 14, № 10 –P. 105110.132.Cohen, I. Differential release of chromatin-bound IL-1alpha discriminatesbetween necrotic and apoptotic cell death by the ability to induce sterile102inflammation / I. Cohen, P.
Rider, Y. Carmi, et al. // Proc Natl Acad Sci USA. –2010. - №107(6). – Р.2574-2579.133.Concia, E. Osteomyelitis: clinical update for practical guidelines / E.Concia, N. Prandini, L. Massari, F. Ghisellini, et al. // Nucl. Med. Commun. –2006 – V. 27, №8. – Р. 645-660.134.De Lalla, F. Randomized prospective controlled trial of recombinantgranulocyte-colony stimulating factor as adjunctive therapy for limb-threateningdiabetic foot infection / F.
De Lalla, G. Pellizzer, M. Strazzabosco et al. //Antimicrob. Agents Chemother. – 2001. – V. 45. – Р. 1094-1098.135.Di Paolo, N.C. Virus binding to a plasma membrane receptor triggersinterleukin-1 alpha-mediated proinflammatory macrophage response in vivo /N.C. Di Paolo, E.A. Miao, Y. Iwakura, et al. // Immunity. – 2009.
-№31(1). –Р.110-121.136.Dinarello, C.A. How interleukin-1beta induces gouty arthritis / C.A.Dinarello // Arthritis Rheum. – 2010. - №62(11). – Р.3140-3144.137.Dinarello, C.A. Immunological and inflammatory functions of theinterleukin-1 family / C.A. Dinarello // Ann Rev Immunol. – 2009. - №27. – Р.519-550.138.Dinarello, C.A.
Why not treat human cancer with interleukin-1 blockade? /C.A. Dinarello // Cancer Metastasis Rev. – 2010. - №29(2). – Р.317-329.139.Dinarello. C.A. Role of IL-1beta in type 2 diabetes / C.A. Dinarello, M.Y.Donath, T. Mandrup-Poulsen // Curr Opin Endocrinol Diabetes Obes. - 2010. №17(4). – Р.314-321.140.Donath, M.Y.
XOMA 052, a potential disease modifying anti-1L–1betaantibody, shows sustained HbA1c reductions 3 months after a single injectionwith no increases in safety parameters in subjects with Type 2 diabetes / M.Y.Donath, C. Weder, A. Brunner, et al. // Diabetes. – 2009. -№58. – Р.30.141.Eigenbrod, T.
Cutting edge: critical role for mesothelial cells in necrosis-induced inflammation through the recognition of IL-1 alpha released from dying103cells / T. Eigenbrod, J.H. Park, J. Harder // J Immunol. – 2008. -№181(12). –Р.8194-8198.142.Eiling, E. Schnitzler syndrome: treatment failure to rituximab but responseto anakinra / E. Eiling, M. Moller, I. Kreiselmaier // J Am Acad Dermatol. –2007.
- №57(2). – Р.361-364.143.El Maghraby, T.A. Nuclear medicine methods for evaluation of skeletalinfection among other diagnostic modalities / T.A. El Maghraby, H.M. Moustafa// Nucl. Med. Mol. Imaging. – 2006. – V. 50, №3. – Р. 167-192.144.Eldor, R. New and experimental approaches to treatment of diabetic footwounds; a comprehensive review of emerging treatment strategies / R. Eldor //Diabetic Medicine.
– 2004. – Vol. 21. – p. 1161-1174.145.Epstein, D. Surgical Perspective in Treatment of Diabetic Foot Ulcer / D.Epstein, J. Corson // Wounds. – 2001. – Vol. 13. - №2. – P. 59-65.146.Esterhai, J.L. Jr, Treatment of chronic refractory osteomyelitis withadjunctive hyperbaric oxygen / J.L. Jr. Esterhai, J. Pisarello, C.T. Brighton, R.B.Heppenstall, H. Gelman, G. Goldstein // Orthop Rev.
– 1988. – V. 17, №8. – Р.809-815.147.Fisher, R. Vessel injury and capillary leak / R. Fisher, C. Are, A. Barbul //Crypt Care Med. – 2004. – Vol. 31. - №8. – P. 502-511.148.Frykberg, R. American college of foot and ankle surgeons. Diabetic footdisorders. A clinical practice guideline. / R. Frykberg, T. Zgonis, D.G. Armstrong// J.
Foot Ankle Surg. – 2006. - Vol. 45. - №2. – P. 2819-2828149.Frykberg, R. Diabetic foot disorders: a clinical practice guideline / R.Frykberg, Armstrong D.G. // J. Foot Ankle Surg. – 2000. - Vol. 39. - №2. – P. 60.150.Frykberg, R. Management of the diabetic Charcot foot. / R. Frykberg, E.Mendeszoon // Diab. Med. Res. Rev. – 2000. – V.16 – P. 59-65.151.Frykberg, R. Surgical management of diabetic foot infections andosteomyelitis / R.
Frykberg, T. Zgonis // Clin. Podiatr. Med. Surg. – 2007. – vol.24. – p. 469-482.104152.Game, F. Management of osteomyelitis of the foot in diabetes mellitus / F.Game // Nat. rev. Endocrinol. – 2010. – vol. 6. – p. 336-349.153.Garlanda, C. TIR8/SIGIRR: an IL-1R/TLR family member with regulatoryfunctions in inflammation and T cell polarization / C.
Garlanda, H.J. Anders, A.Mantovani // Trends Immunol. – 2009. - №30(9). – Р.439-446.154.Gattorno, M. Pattern of interleukin-1beta secretion in response tolipopolysaccharide and ATP before and after interleukin-1 blockade in patientswith CIAS1 mutations / M. Gattorno, S. Tassi, S. Carta, et al. // Arthritis Rheum.– 2007. - №56(9). – Р. 3138-3148.155.Gattorno, M. The pattern of response to anti-interleukin-1 treatmentdistinguishes two subsets of patients with systemic-onset juvenile idiopathicarthritis / M. Gattorno, A. Piccini, D. Lasiglie, et al. // Arthritis Rheum.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
